Company: PRME
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023486
Chunk: 43

Company: Prime Medicine, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---
 except those discussed below.Bristol-Myers Squibb — Related PartySupplemental information related to the BMS Collaboration Agreement consisted of the following:(in thousands)March 31,2025December 31,2024Collaboration receivable — related party$17 $— Deferred revenue — related party$8,214 $7,092 Deferred revenue, net of current — related party$60,658 $63,218 Three Months Ended March 31,(in thousands)20252024Revenue recognized that was included in contract liability at the beginning of the period$1,419 $— Revenue recognized from performance obligations fully or partially satisfied in previous periods$— $— As of March 31, 2025, the aggregate amount of the transaction price allocated to performance obligations under the BMS Collaboration Agreement that are partially unsatisfied was $70.3 million. The Company recognizes the portion of the transaction price as the single performance obligation is satisfied, using an input method, in proportion to costs incurred to date as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation.

10.Net Loss per Share 

Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:Three Months EndedMarch 31,(in thousands, except share and per share amounts)20252024Numerator:Net loss attributable to common stockholders$(51,890)$(45,761)Denominator:Weighted-average common shares outstanding, basic and diluted130,884,490 104,466,178 Net loss per share attributable to common stockholders, basic and diluted$(0.40)$(0.44)The weighted-average number of common shares outstanding used in the basic and diluted net loss per share calculations includes the weighted-average effect of pre-funded warrants sold by the Company to purchase 3,200,005 shares of the Company's common stock. The shares of common stock underlying the pre-funded warrants are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested, and the pre-funded warrants are immediately exercisable upon their issuance date.Diluted net loss per share available to common stockholders is computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, preferred stock, unvested restricted stock and stock options to purchase common stock were considered common stock equivalents but had been excluded from the calculation of diluted